Antares Pharma, Inc. (ATRS)

[H2R]

New SA article on ATRS, Xyosted focus :)

https://seekingalpha.com/article/4081629-antares-pharma-focus-xyosted

Summary:
Beyond multiple catalysts near term, Xyosted presents by far the largest opportunity for the company.

Xyosted has an FDA PDUFA date of October 20, 2017.

Due to a high level of success of a 52-week phase 3 study in advance of submitting an NDA, FDA approval appears very likely.

If approved, Xyosted is poised to be the premier testosterone replacement therapy which will be embraced by the medical community.

[...]

When the company developed and patented the QuickShot device it had at least one specific purpose in mind, which is the novel delivery of a drug that has been around since the 1950s. Both the IP portfolio and the huge opportunity in FDA approval of Xyosted have received little recognition in the market to date. The billion-dollar plus opportunity for Xyosted will surely gain the attention of much larger pharma players as FDA approval nears. While Antares remains an ideal acquisition candidate, an M&A deal will likely occur much sooner than many investors realize. As the company and stock continue to build momentum, it should be an exciting time for Antares investors.